EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia

Hanna Franziska Nowotny, Lea Tschaidse, Matthias K Auer, Nicole Reisch

Clinical Endocrinology · 2024-10 · 101 (4) · 359-370

DOI: 10.1111/cen.15131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, online erschienen am 10.10.2024. Verfasst von Hanna Franziska Nowotny und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eva Luise und Horst Köhler Stiftung, Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of patients with congenital adrenal hyperplasia (CAH) poses challenges during pregnancy and prenatal stages, impacting fertility differently in men and women. Women with CAH experience menstrual irregularities due to androgen and glucocorticoid precursor interference with endometrial development and ovulation. Genital surgeries for virilization and urogenital anomalies further impact fertility and sexual function, leading to reduced heterosexual relationships among affected women. Fertility rates vary, with a lower prevalence of motherhood, primarily among those with classic CAH, necessitating optimized hormonal therapy for conception. Monitoring optimal disease control during pregnancy poses challenges due to hormonal fluctuations. Men with CAH often experience hypogonadotrophic hypogonadism and complications like testicular adrenal rest tissue, impacting fertility. Regular monitoring and intensified glucocorticoid therapy may restore spermatogenesis. Genetic counselling is vital to comprehend transmission risks and prenatal implications. Prenatal dexamethasone treatment in affected female fetuses prevents virilization but raises ethical and safety concerns, necessitating careful consideration and further research. The international “PREDICT” study aims to establish safer and more effective prenatal therapy in CAH, evaluating dosage, safety, and long‐term effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHumansFemalePregnancyMalePrenatal CarePregnancy ComplicationsGlucocorticoids

Stichwörter der Autor:innen

congenital adrenal hyperplasiafertilitypregnanyprenatal dexamethasone treatment

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.

Förderung

  • Eva Luise und Horst Köhler Stiftung
  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung.

Zitieren

APA

Nowotny, H. F., Tschaidse, L., Auer, M. K., & Reisch, N. (2024). Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia. Clinical Endocrinology, 101(4), 359-370. https://doi.org/10.1111/cen.15131

Vancouver

Nowotny HF, Tschaidse L, Auer MK, Reisch N. Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia. Clinical Endocrinology. 2024;101(4):359-370. doi:10.1111/cen.15131

BibTeX
@article{Nowotny2024,
  author = {Nowotny, Hanna Franziska and Tschaidse, Lea and Auer, Matthias K and Reisch, Nicole},
  title = {Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {101},
  number = {4},
  pages = {359--370},
  doi = {10.1111/cen.15131}
}
Kostenlos starten →